ATE491043T1 - Diagnosegerät zur diagnose gutartiger gegenüber bösartigen schilddrüsenläsionen - Google Patents

Diagnosegerät zur diagnose gutartiger gegenüber bösartigen schilddrüsenläsionen

Info

Publication number
ATE491043T1
ATE491043T1 AT05735973T AT05735973T ATE491043T1 AT E491043 T1 ATE491043 T1 AT E491043T1 AT 05735973 T AT05735973 T AT 05735973T AT 05735973 T AT05735973 T AT 05735973T AT E491043 T1 ATE491043 T1 AT E491043T1
Authority
AT
Austria
Prior art keywords
diagnosis
diagnostic device
malignant thyroid
thyroid lesions
versus malignant
Prior art date
Application number
AT05735973T
Other languages
English (en)
Inventor
Steven Libutti
Chiara Mazzanti
Martha A Zeiger
Christopher B Umbricht
Original Assignee
Us Gov Health & Human Serv
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Univ Johns Hopkins filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE491043T1 publication Critical patent/ATE491043T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Test And Diagnosis Of Digital Computers (AREA)
  • Monitoring And Testing Of Transmission In General (AREA)
  • Stereo-Broadcasting Methods (AREA)
AT05735973T 2004-04-09 2005-04-11 Diagnosegerät zur diagnose gutartiger gegenüber bösartigen schilddrüsenläsionen ATE491043T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56090004P 2004-04-09 2004-04-09
US62264304P 2004-10-26 2004-10-26
PCT/US2005/012289 WO2005100608A2 (en) 2004-04-09 2005-04-11 Diagnostic tool for diagnosing benign versus malignant thyroid lesions

Publications (1)

Publication Number Publication Date
ATE491043T1 true ATE491043T1 (de) 2010-12-15

Family

ID=35150567

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05735973T ATE491043T1 (de) 2004-04-09 2005-04-11 Diagnosegerät zur diagnose gutartiger gegenüber bösartigen schilddrüsenläsionen

Country Status (5)

Country Link
US (2) US7901881B2 (de)
EP (1) EP1756303B1 (de)
AT (1) ATE491043T1 (de)
DE (1) DE602005025211D1 (de)
WO (1) WO2005100608A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7901881B2 (en) 2004-04-09 2011-03-08 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic tool for diagnosing benign versus malignant thyroid lesions
JP2007199948A (ja) * 2006-01-25 2007-08-09 Dainakomu:Kk 疾患リスク情報表示装置およびプログラム
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP1975252A1 (de) * 2007-03-29 2008-10-01 INSERM (Institut National de la Santé et de la Recherche Medicale) Verfahren zur Vorhersage oder Diagnose einer Schilddrüsenkrankheit
US9234244B2 (en) * 2007-08-27 2016-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnostic tool for diagnosing benign versus malignant thyroid lesions
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US20110251091A1 (en) 2008-09-12 2011-10-13 Cornell University Thyroid tumors identified
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
JP6257125B2 (ja) * 2008-11-17 2018-01-10 ベラサイト インコーポレイテッド 疾患診断のための分子プロファイリングの方法および組成物
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
CA2753916C (en) 2009-04-29 2020-08-25 Genomedx Biosciences Inc. Systems and methods for expression-based classification of thyroid tissue
EP3360978A3 (de) 2009-05-07 2018-09-26 Veracyte, Inc. Verfahren zur diagnose von schilddrüsenerkrankungen
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
EP2519651A2 (de) 2009-12-30 2012-11-07 Rigshospitalet Klassifizierung von follikulärer thyroidneoplasie auf grundlage von mrna-expression
US8485975B2 (en) 2010-06-07 2013-07-16 Atheropoint Llc Multi-resolution edge flow approach to vascular ultrasound for intima-media thickness (IMT) measurement
US8313437B1 (en) 2010-06-07 2012-11-20 Suri Jasjit S Vascular ultrasound intima-media thickness (IMT) measurement system
US8532360B2 (en) 2010-04-20 2013-09-10 Atheropoint Llc Imaging based symptomatic classification using a combination of trace transform, fuzzy technique and multitude of features
US8708914B2 (en) 2010-06-07 2014-04-29 Atheropoint, LLC Validation embedded segmentation method for vascular ultrasound images
US8639008B2 (en) * 2010-04-20 2014-01-28 Athero Point, LLC Mobile architecture using cloud for data mining application
EP2569626B1 (de) * 2010-05-11 2019-11-27 Veracyte, Inc. Verfahren und zusammensetzungen zur diagnose von leiden
US20190100809A1 (en) * 2010-05-11 2019-04-04 Veracyte, Inc. Algorithms for disease diagnostics
CA2858581A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US11035005B2 (en) 2012-08-16 2021-06-15 Decipher Biosciences, Inc. Cancer diagnostics using biomarkers
KR101993716B1 (ko) * 2012-09-28 2019-06-27 삼성전자주식회사 카테고리별 진단 모델을 이용한 병변 진단 장치 및 방법
WO2014186036A1 (en) 2013-03-14 2014-11-20 Allegro Diagnostics Corp. Methods for evaluating copd status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CN114606309A (zh) 2014-11-05 2022-06-10 威拉赛特公司 使用机器学习和高维转录数据的诊断***和方法
EP3504348B1 (de) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Verwendung von genomischen signaturen zur vorhersage des ansprechens von patienten mit prostatakrebs auf postoperative strahlentherapie
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
EP3593140A4 (de) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. Subtypisierung von prostatakrebs zur vorhersage der reaktion auf eine hormontherapie
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
EP4023770A1 (de) 2021-01-05 2022-07-06 Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Oddzial w Gliwicach Verfahren zur untersuchung von genen zur diagnose von schilddrüsentumoren, set zur diagnose von schilddrüsentumoren und anwendung

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US6974666B1 (en) 1994-10-21 2005-12-13 Appymetric, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
JP2002515738A (ja) 1996-01-23 2002-05-28 アフィメトリックス，インコーポレイティド 核酸分析法
WO1997029212A1 (en) 1996-02-08 1997-08-14 Affymetrix, Inc. Chip-based speciation and phenotypic characterization of microorganisms
US6458530B1 (en) 1996-04-04 2002-10-01 Affymetrix Inc. Selecting tag nucleic acids
US6436642B1 (en) 1999-04-20 2002-08-20 Curagen Corporation Method of classifying a thyroid carcinoma using differential gene expression
US20040219521A1 (en) 2000-01-21 2004-11-04 Tang Y. Tom Novel nucleic acids and polypeptides
AU2002362309A1 (en) 2001-09-14 2003-04-01 Gene Logic, Inc. Genes associated with malignant neoplasms
AU2002366951A1 (en) * 2001-12-10 2003-07-09 Nuvelo,Inc. Novel nucleic acids and polypeptides
WO2003065873A2 (en) 2002-02-01 2003-08-14 Seattle Genetics, Inc. Sga-1m, a cancer associated antigen, and uses thereof
CA2488382A1 (en) 2002-06-05 2003-12-18 Case Western Reserve University Methods and compositions for detecting cancers
US7901881B2 (en) * 2004-04-09 2011-03-08 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic tool for diagnosing benign versus malignant thyroid lesions

Also Published As

Publication number Publication date
EP1756303B1 (de) 2010-12-08
US20110177971A1 (en) 2011-07-21
EP1756303A2 (de) 2007-02-28
US7901881B2 (en) 2011-03-08
US20080145841A1 (en) 2008-06-19
DE602005025211D1 (de) 2011-01-20
WO2005100608A2 (en) 2005-10-27
WO2005100608A3 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
ATE491043T1 (de) Diagnosegerät zur diagnose gutartiger gegenüber bösartigen schilddrüsenläsionen
WO2009029266A3 (en) Diagnostic tool for diagnosing benign versus malignant thyroid lesions
WO2008050255A3 (en) Contrast agents for detecting prostate cancer
MX2010000405A (es) Seleccion de farmacos para terapia de cancer de pulmon usando arreglos a base de anticuerpos.
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
WO2008060363A3 (en) Tumor associated markers in the diagnosis of prostate cancer
WO2008008786A3 (en) Pre- and intra- operative imaging of bladder cancer
IL207637A (en) Choosing a Breast Cancer Remedy Using Antibody-Based Arrays
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
WO2005111211A8 (en) Micronas and uses thereof
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2005123993A3 (en) Phage microarray profiling of the humoral response to disease
MX2007016322A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
FR2883562B1 (fr) Chelates lipophiles et leur utilisation en imagerie
WO2007143037A3 (en) Gene methylation in cancer diagnosis
EP1848466A4 (de) Mri-kontrastmittel zur diagnose und prognose von tumoren
WO2006015079A3 (en) Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008030986A3 (en) Molecular diagnosis and classification of malignant melanoma
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer
PH12016500047A1 (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211-seqid2)
NO20090174L (no) Genfamilie (LBFL313) assosiert med kreft i bukspyttkjertel
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
MX2010005057A (es) Metodos y composiciones para uso de diagnostico en pacientes de cancer.
WO2007080194A3 (en) Use of tpp ii inhibitors in combination with gamma-irradiation for the treatment of cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties